These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22494466)

  • 121. Polypharmacy in Parkinson's disease: risks and benefits with little evidence.
    Csoti I; Herbst H; Urban P; Woitalla D; Wüllner U
    J Neural Transm (Vienna); 2019 Jul; 126(7):871-878. PubMed ID: 31222606
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.
    Mazumder MK; Borah A; Choudhury S
    Med Hypotheses; 2020 Apr; 137():109544. PubMed ID: 31954292
    [TBL] [Abstract][Full Text] [Related]  

  • 123. In silico target fishing for the potential targets and molecular mechanisms of baicalein as an antiparkinsonian agent: discovery of the protective effects on NMDA receptor-mediated neurotoxicity.
    Gao L; Fang JS; Bai XY; Zhou D; Wang YT; Liu AL; Du GH
    Chem Biol Drug Des; 2013 Jun; 81(6):675-87. PubMed ID: 23461900
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Theoretical Study of Monoamine Oxidase B Inhibitors as Drug Candidates for Treatment of Parkinson's Disease.
    Souza LR; Picanço LCS; Brito MFB; Almeida MRS; Marino BLB; Sousa KPA; Ferreira JV; Dos Santos CBR; Silva GM; Silva CHTP; Taft CA; Hage-Melim LIS
    Cent Nerv Syst Agents Med Chem; 2020; 20(2):128-143. PubMed ID: 32065095
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Label-free LC-HRMS-based enzymatic activity assay for the detection of DDC, MAO and COMT inhibitors.
    Harfouche A; Alata W; Leblanc K; Heslaut G; Figadère B; Maciuk A
    J Pharm Biomed Anal; 2022 Apr; 212():114598. PubMed ID: 35152005
    [TBL] [Abstract][Full Text] [Related]  

  • 126. In Silico and In Vivo Studies on Quercetin as Potential Anti-Parkinson Agent.
    Boyina HK; Geethakhrishnan SL; Panuganti S; Gangarapu K; Devarakonda KP; Bakshi V; Guggilla SR
    Adv Exp Med Biol; 2020; 1195():1-11. PubMed ID: 32468451
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Effects of a New Natural Catechol-
    Parrales-Macias V; Harfouche A; Ferrié L; Haïk S; Michel PP; Raisman-Vozari R; Figadère B; Bizat N; Maciuk A
    ACS Chem Neurosci; 2022 Dec; 13(23):3303-3313. PubMed ID: 36347018
    [TBL] [Abstract][Full Text] [Related]  

  • 128. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.
    Dong J; Cui Y; Li S; Le W
    Curr Neuropharmacol; 2016; 14(4):339-55. PubMed ID: 26585523
    [TBL] [Abstract][Full Text] [Related]  

  • 130. In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.
    Lemos A; Melo R; Preto AJ; Almeida JG; Moreira IS; Dias Soeiro Cordeiro MN
    Curr Neuropharmacol; 2018; 16(6):786-848. PubMed ID: 29521236
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Neuroprotective therapies.
    Simon DK; Standaert DG
    Med Clin North Am; 1999 Mar; 83(2):509-23, viii. PubMed ID: 10093591
    [TBL] [Abstract][Full Text] [Related]  

  • 132. A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's disease.
    Venhuis BJ; Rodenhuis N; Wikström HV; Wustrow D; Meltzer LT; Wise LD; Johnson SJ; Pugsley TA; Sundell S; Dijkstra D
    J Med Chem; 2002 Jun; 45(12):2349-51. PubMed ID: 12036342
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 134. [Parkinson disease: interrogations and solutions].
    Allain H; Bentué-Ferrer D
    Presse Med; 1997 Jun; 26(19):909-15. PubMed ID: 9232065
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Current status of symptomatic medical therapy in Parkinson's disease.
    Factor SA
    Neurotherapeutics; 2008 Apr; 5(2):164-80. PubMed ID: 18394561
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents.
    Di Stefano A; Marinelli L; Eusepi P; Ciulla M; Fulle S; Di Filippo ES; Magliulo L; Di Biase G; Cacciatore I
    Biomolecules; 2019 Jun; 9(6):. PubMed ID: 31216771
    [TBL] [Abstract][Full Text] [Related]  

  • 137. TP10-Dopamine Conjugate as a Potential Therapeutic Agent in the Treatment of Parkinson's Disease.
    Rusiecka I; Ruczyński J; Kozłowska A; Backtrog E; Mucha P; Kocić I; Rekowski P
    Bioconjug Chem; 2019 Mar; 30(3):760-774. PubMed ID: 30653302
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Modelling of Parkinson's disease in mice.
    Chesselet MF; Richter F
    Lancet Neurol; 2011 Dec; 10(12):1108-18. PubMed ID: 22094131
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents.
    Ribaudo G; Zanforlin E; Canton M; Bova S; Zagotto G
    Nat Prod Res; 2018 Jun; 32(12):1395-1401. PubMed ID: 28691859
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.
    Gunay MS; Ozer AY; Chalon S
    Curr Neuropharmacol; 2016; 14(4):376-91. PubMed ID: 26714584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.